Immunomedics Inc
IMMU
IMMU was delisted on the 22nd of October, 2020.
130 hedge funds and large institutions have $766M invested in Immunomedics Inc in 2017 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 51 increasing their positions, 40 reducing their positions, and 21 closing their positions.
133% more funds holding in top 10
Funds holding in top 10: 3 → 7 (+4)
74% more capital invested
Capital invested by funds: $440M → $766M (+$326M)
56% more call options, than puts
Call options by funds: $41.9M | Put options by funds: $26.9M
29% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 21
28% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 40
5% more funds holding
Funds holding: 124 → 130 (+6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$27.9M |
| 2 |
O
OrbiMed
New York
|
+$26M |
| 3 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$21.1M |
| 4 |
Millennium Management
New York
|
+$17M |
| 5 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
+$12.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$21.9M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$7.74M |
| 3 |
6CM
683 Capital Management
New York
|
-$3.51M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.81M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.12M |
IMMU Hedge Fund Activity: Q2 2017 in Review
130 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Immunomedics Inc (IMMU) for Q2 2017, worth a combined $766M — up 74% from $440M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new IMMU positions and 21 closed out — a net gain of 6 holders — while 51 added to existing stakes and 40 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $27.9M. The largest seller was Redmile Group, exiting entirely with an estimated $21.9M sold.
- 130 institutional investors held Immunomedics Inc (IMMU) as of Q2 2017, up from 124 in Q1 2017.
- Funds reported $766M of Immunomedics Inc stock for Q2 2017, up 74% quarter-over-quarter.
- 27 funds opened new Immunomedics Inc positions in Q2 2017 and 21 closed out, a net change of +6 holders.
- The largest Immunomedics Inc buyer in Q2 2017 was Fidelity Investments, an estimated $27.9M added.
- The largest Immunomedics Inc seller in Q2 2017 was Redmile Group, an estimated $21.9M sold.
Based on aggregated 13F filings for Q2 2017.